LONDON (Reuters Health) Oct 14 –
Britain’s medicines cost-effectiveness watchdog is set to recommend Roche’s influenza treatment oseltamivir (Tamiflu), but only for high-risk patients who can begin therapy within 48 hours of the onset of symptoms.
The at-risk groups include people over 65; patients with chronic respiratory diseases, such as asthma; patients with significant heart disease, diabetes, or an impaired immune system; and all those living in nursing homes.
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!